Products for Research Use Only
RegisterLogin

Drospirenone

CAT: 0804-HY-B0111-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0111-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Drospirenone (Dihydrospirorenone) is an orally active fourth-generation progestin that interacts with the progesterone receptor (PR) and androgen receptor (AR) . Drospirenone significantly decreases both plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) via the AR. Drospirenone can produce DNA damage in bone marrow cells of female mice. [1][2][3][4].
CAS Number
67392-87-4
Product Name Alternative
Dihydrospirorenone
UNSPSC
12352005
Hazard Statement
H360
Target
Androgen Receptor; Progesterone Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/drospirenone.html
Purity
98.45
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
C[C@@]12[C@](OC3=O)(CC3)[C@@H](C4)[C@@H]4[C@@]1([H])[C@@]([C@@H]5[C@H]6C5)([H])[C@]([C@](C6=CC7=O)(CC7)C)([H])CC2
Molecular Formula
C24H30O3
Molecular Weight
366.49
Precautions
H360
References & Citations
[1]Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54 (4) : p. 243-51.|[2]Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51 (2) : p. 99-110.|[3]Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7 (1) : p. 103-11.|[4]Marqueño A, et al. Drospirenone induces the accumulation of triacylglycerides in the fish hepatoma cell line, PLHC-1 [J]. Science of The Total Environment, 2019, 692: 653-659.|[5]Sabouni R, et al. Drospirenone effects on the plasminogen activator system in immortalized human endometrial endothelial cells [J]. Reproductive sciences, 2021, 28: 1974-1980.|[6]Mir A H, et al. Genotoxic effects of drospirenone and ethinylestradiol in human breast cells (in vitro) and bone marrow cells of female mice (in vivo) [J]. Drug and Chemical Toxicology, 2022, 45 (4) : 1493-1499.|[7]Motivala A, et al. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? [J]. Drugs, 2007, 67: 647-655.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
B1520-25Drospirenone
AR-D02467-01Drospirenone Impurity (Drospirenone Lactol)

Popular Products